ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026.

ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth

Product revenue in the quarter was up 168% year over year to $44.2 million. The increase comes on the heels of ANKTIVA, an FDA-approved treatment for non-muscle invasive bladder cancer, commercial launch. The significant product revenue builds on 2025 net product revenue of $113 million, a 700% increase over 2024. ImmunityBio exited the quarter with $380.9 million in cash and cash equivalents.

ANKTIVA is the company’s lead product, expected to solidify its revenue base as it has been approved across five jurisdictions representing 34 countries. Its continued momentum underscores growing physician adoption and disciplined commercial execution. Following strong growth in 2025, ImmunityBio is focused on scaling in the US and expanding into global markets to pursue new revenue streams.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation immunotherapies that activate a patient’s natural killer (NK) cells and T cells to treat cancers and infectious diseases. Its lead FDA-approved drug, ANKTIVA (N-803), is used in combination with BCG to treat non-muscle invasive bladder cancer (NMIBC).

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy in 2026.

Disclosure: None. Follow Insider Monkey on Google News.